Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 188

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy

Open access
van den Brand, Jan A.J.G., Ruggenenti, Piero, Chianca, Antonietta, Hofstra, Julia M., Perna, Annalisa, Ruggiero, Barbara, Wetzels, Jack F.M., Remuzzi, Giuseppe · 2017 · Journal of the American Society of Nephrology

Abstract

Guidelines recommend steroid plus cyclical cyclophosphamide (S t-C p) therapy for patients with idiopathic membranous nephropathy at high risk of progression to ESRD. Rituximab (R tx) may be a safer alternative. In this retrospective, observational cohort study, we compared time to any adverse event (primary outcome); serious or nonserious events; partial and complete remission of the nephrotic syndrome; and a composite of doubling of serum creatinine, ESRD, or death between 100 R tx-treated patients and 103 patients who received daily S t-C p. We monitored patients with standardized protocols and adjusted for baseline characteristics by Cox regression. Over a median follow-up of 40 months, the R tx group had significantly fewer adverse events than the S t-C p group (63 versus 173;P<0.001), both serious (11 versus 46;P<0.001) and nonserious (52 versus 127;P<0.001). Cumulative incidence of any first (35.5% versus 69.0%;P<0.001), serious (16.4% versus 30.2%;P=0.002), or nonserious (23.6% versus 60.8%;P<0.001) event was significantly lower with R tx. Adjusted hazard ratios (95% confidence intervals) between R tx and S t-C p groups were 0.27 (0.16 to 0.44) for any first adverse event, 0.32 (0.15 to 0.68) for serious adverse events, and 0.23 (0.13 to 0.41) for nonserious adverse events. Although the cumulative incidence of partial remission was lower in the R tx group, rates of complete remission and the composite renal end point did not differ significantly between groups. Because of its superior safety profile, we suggest that R tx might replace S t-C p as first-line immunosuppressive therapy in patients with idiopathic membranous nephropathy and nephrotic syndrome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2016091022

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 188

Metadata

Authors
van den Brand, J. A. J. G., Ruggenenti, P., Chianca, A., Hofstra, J. M., Perna, A., Ruggiero, B., Wetzels, J. F. M., & Remuzzi, G.
Venue
Journal of the American Society of Nephrology
Published
2017-05-09
Volume
28
Issue
9
Pages
2729-2737
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2613205117
Cited by
188
References
2
FWCI
10.29
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. https://app.cochat.ai/papers/10.1681/asn.2016091022
The paper
van den Brand, J. A. J. G., Ruggenenti, P., Chianca, A., Hofstra, J. M., Perna, A., Ruggiero, B., Wetzels, J. F. M., & Remuzzi, G. (2017). Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2016091022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.